Pharvaris N.V. Ordinary Shares
Symbol: PHVS (NASDAQ)
23.62
▲ (1.57%) 0.365
Company Description:
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
Key Stats
- Today's Open: $23.39
- Today's High: $24.985
- Today's Low: $23.25
- Today's Volume: 61.08K
- Yesterday Close: $23.25
- Yesterday High: $24.83
- Yesterday Low: $23.22
- Yesterday Volume: 61.50K
- Last Min Volume: 1
- Last Min High: $23.615
- Last Min Low: $23.615
- Last Min VWAP: $23.615
Company Profile
- Name: Pharvaris N.V. Ordinary Shares
- Website: https://www.pharvaris.com
- Listed Date: 2021-02-05
- Location: ,
- Market Status: Active
- CIK Number: 0001830487
- SIC Code:
- SIC description:
- Market Cap: $1.49B
- Round Lot: 100
- Outstanding Shares: 64.30M
- Asset Type: CS
RECENT FILINGS FOR PHVS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-08 | 6-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-12 | 6-K | View |
| 2025-07-24 | 6-K | View |
| 2025-07-24 | 424B5 | View |
| 2025-07-23 | FWP | View |
| 2025-07-22 | 424B5 | View |
| 2025-07-14 | 144 | View |
| 2025-07-11 | 144 | View |
| 2025-07-10 | 6-K | View |
| 2025-06-27 | 6-K | View |
| 2025-06-10 | 6-K | View |
| 2025-05-13 | 6-K | View |
| 2025-04-07 | 6-K | View |
| 2025-04-07 | 20-F | View |
| 2025-01-13 | 6-K | View |
| 2024-12-02 | 144 | View |
| 2024-11-13 | 6-K | View |
| 2024-10-31 | 144 | View |
| 2024-10-24 | 144 | View |
Latest News on PHVS